Intralesional rituximab in the treatment of indolent primary cutaneous B-cell lymphomas: an epidemiological observational multicentre study. The Spanish Working Group on Cutaneous Lymphoma. [artículo]
Por: Ortiz Romero, Pablo Luis [Dermatología Médico-Quirúrgica y Venereología]
| Rosales Trujillo, Belén [Dermatología Médico-Quirúrgica y Venereología].
Colaborador(es): Servicio de Dermatología Médico-Quirúrgica y Venereología.
Editor: The British journal of dermatology, 2012Descripción: 167(1):174-9.Recursos en línea: Solicitar documento Resumen: BACKGROUND: Intravenous rituximab is a safe and effective option for the treatment of systemic non-Hodgkin B-cell lymphoma. The effectiveness of intralesional rituximab (ILR) in primary cutaneous B-cell lymphomas (PCBL) has been described in a small number of patients.
| Tipo de ítem | Ubicación actual | Signatura | Estado | Fecha de vencimiento |
|---|---|---|---|---|
Artículo
|
PC9227 (Navegar estantería) | Disponible |
Formato Vancouver:
Peñate Y, Hernández-Machín B, Pérez-Méndez LI, Santiago F, Rosales B, Servitje O, et al. Intralesional rituximab in the treatment of indolent primary cutaneous B-cell lymphomas: an epidemiological observational multicentre study. The Spanish Working Group on Cutaneous Lymphoma. Br J Dermatol. 2012 Jul;167(1):174-9.
PMID: 22356294
Contiene 12 referencias
BACKGROUND: Intravenous rituximab is a safe and effective option for the treatment of systemic non-Hodgkin B-cell lymphoma. The effectiveness of intralesional rituximab (ILR) in primary cutaneous B-cell lymphomas (PCBL) has been described in a small number of patients.
No hay comentarios para este ejemplar.